AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Aeglea Bio TherapeuticsNeuBase TherapeuticsOASMIA PHARMACE/ADRTheratechnologiesEvelo Biosciences
SymbolNASDAQ:AGLENASDAQ:NBSENASDAQ:OASMOTCMKTS:THERFNASDAQ:EVLO
Price Information
Current Price$8.90$7.80$1.55N/A$4.47
52 Week RangeBuyBuyN/AHoldHold
Beat the Market™ Rank
Overall Score2.11.90.51.11.6
Analysis Score3.53.50.03.03.2
Community Score2.82.82.52.42.4
Dividend Score0.00.00.00.00.0
Ownership Score4.03.00.00.02.0
Earnings & Valuation Score0.00.00.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyN/AHoldHold
Consensus Price Target$13.33$15.60N/A$6.00$11.67
% Upside from Price Target49.81% upside100.00% upsideN/A∞ upside161.00% upside
Trade Information
Market Cap$392.84 million$180.34 million$116.20 million$117.73 million$144.52 million
Beta2.060.490.960.581.1
Average Volume129,104193,26824,78025,67786,323
Sales & Book Value
Annual Revenue$3.89 millionN/A$220,000.00$45.18 millionN/A
Price / Sales102.03N/A528.200.00N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/A177.07N/A
Book Value$0.96 per share$0.17 per share$0.63 per share$0.47 per share$1.22 per share
Price / Book9.27N/A2.460.00N/A
Profitability
Net Income$-78,250,000.00$-26,960,000.00$-18,950,000.00$-4,660,000.00$-85,470,000.00
EPS($2.45)N/AN/AN/A($2.67)
Trailing P/E RatioN/A0.000.000.00N/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-8,633.64%-11.57%N/A
Return on Equity (ROE)-113.09%-446.35%-43.94%-14.31%-125.94%
Return on Assets (ROA)-87.34%-333.32%-28.92%-4.25%-85.77%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.11%N/AN/A1.70%0.50%
Current Ratio3.17%1.74%0.80%2.69%4.89%
Quick Ratio3.17%1.74%0.73%2.19%4.89%
Ownership Information
Institutional Ownership Percentage46.09%15.85%0.11%1.37%85.24%
Insider Ownership Percentage12.60%12.50%N/AN/A59.10%
Miscellaneous
Employees6112573275
Shares Outstanding44.59 million23.12 million74.97 million76.95 million32.33 million
Next Earnings Date8/4/2020 (Estimated)8/12/2020 (Estimated)N/AN/A8/4/2020 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.